Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,300 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $159.45, for a total transaction of $207,285.00. Following the completion of the sale, the chief executive officer now directly owns 278,615 shares of the company’s stock, valued at $44,425,161.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
JAZZ stock opened at $164.41 on Wednesday. Jazz Pharmaceuticals PLC has a 12 month low of $128.58 and a 12 month high of $184.00. The company has a market cap of $9.85 billion, a P/E ratio of 17.20, a price-to-earnings-growth ratio of 0.89 and a beta of 1.06. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The business had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. During the same period in the prior year, the business earned $3.22 earnings per share. The business’s quarterly revenue was up 14.0% on a year-over-year basis. Equities analysts predict that Jazz Pharmaceuticals PLC will post 11.71 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $201.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday. Piper Jaffray Companies set a $213.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, October 19th. Mizuho reaffirmed a “neutral” rating and issued a $173.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, October 15th. BidaskClub raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 28th. Finally, Leerink Swann upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, August 17th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $192.65.
Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its position in shares of Jazz Pharmaceuticals by 300.7% in the 3rd quarter. SG Americas Securities LLC now owns 7,949 shares of the specialty pharmaceutical company’s stock valued at $1,336,000 after acquiring an additional 5,965 shares in the last quarter. LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 3.5% in the 3rd quarter. LSV Asset Management now owns 298,292 shares of the specialty pharmaceutical company’s stock valued at $50,151,000 after acquiring an additional 9,956 shares in the last quarter. Systematic Financial Management LP lifted its position in shares of Jazz Pharmaceuticals by 1.0% in the 3rd quarter. Systematic Financial Management LP now owns 143,216 shares of the specialty pharmaceutical company’s stock valued at $24,079,000 after acquiring an additional 1,368 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $8,868,000. Finally, Janney Montgomery Scott LLC lifted its position in shares of Jazz Pharmaceuticals by 72.6% in the 3rd quarter. Janney Montgomery Scott LLC now owns 6,334 shares of the specialty pharmaceutical company’s stock valued at $1,065,000 after acquiring an additional 2,665 shares in the last quarter. 92.95% of the stock is owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.